Advertisement

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Peter Clark, MA, MD, FRCP: A Payer Perspective

Amit Sanyal, MD: A Clinician’s Perspective

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement

Aug

12

Today In Oncology

Global Survey Identifies Barriers to Integrative Oncology Use in Cancer Care

AI Biomarker May Guide Adjuvant Chemotherapy in Resected Pancreatic Cancer

First-in-Class Bispecific ADC Shows Activity in Relapsed Extensive-Stage Small Cell Lung Cancer

NIH-Funded International Research Yields Patient-Derived Tumor Compendium

Stanford Appoints New Leader to Expand Impact in Early Drug Development

Advertisement

© 2026 HSP News Service, L.L.C.